liver inflammation
MCC950 treatment normalized hepatic caspase 1 and IL-1b expression, plasma IL-1b, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis.